Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309997 | 1.00 | ADRA1A (0.41) | ADRA1AADRA1DAKT1GAAPOLB | |
| SCHEMBL2946130 | 1.00 | ADRA1A (0.41) | ADRA1AADRA1DAKT1GAAPOLB | |
| SCHEMBL234731 | 0.98 | — | — | |
| Benzimidazole SCHEMBL7463429 | 0.78 | ADRA1A (0.41) | ADRA1AADRA1DRAB9AHTT | |
| SCHEMBL550173 | 0.74 | ADRA1A (0.40) | ADRA1AADRA1DAKT1POLBRAB9A | |
| SCHEMBL1917618 | 0.74 | ADRA1A (0.40) | ADRA1AADRA1DAKT1RAB9A | |
| SCHEMBL31698792 | 0.74 | ADRA1A (0.33) | ADRA1ARAB9A | |
| SCHEMBL13911357 | 0.70 | GAA (0.50) | GAAPOLBRAB9ACHEK1TSHR | |
| SCHEMBL19661014 | 0.70 | ADRA1A (0.47) | ADRA1AADRA1DAKT1POLBRAB9A | |
| SCHEMBL12082637 | 0.70 | AKT1 (0.39) | ADRA1AADRA1DAKT1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-5409947-A | Treating hypertension, congestive heart failure | KOTOBUKI SEIYAKU CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | ADRA1A 557/4885ADRA1D 445/4885AKT1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.